Latest News from the AGILE COVID-19 Trials
AGILE trial reports on antiviral activity of molnupiravir in vaccinated and unvaccinated individuals infected with contemporaneous variants of SARS-CoV-2
The antiviral drug molnupiravir received regulatory approval for treating people with mild to moderate COVID-19…
Learning and confirming in publicly funded antiviral trials
Reporting the phase 2 results from the UK AGILE CST-2 study of molnupiravir for SARS-CoV-2…
First antiviral pill to treat Covid-19 approved in UK
A “game-changing” antiviral pill that is part of the AGILE Coronavirus Drug Testing Initiative has…
AGILE Covid-19 drug testing platform opens new trial in South Africa
A new international trial to assess whether high doses of the antiparasitic drug nitazoxanide could…
First patient dosed in latest stage of AGILE COVID-19 drug trial
LIVERPOOL, England, 20 April 2021 — The University of Liverpool, Liverpool School of Tropical Medicine,…
People across the south to be part of pioneering research in the fight against COVID-19
People across the south are being asked to play their part in helping vital research…